CXCL16 and non-small cell lung carcinoma: The median serum CXCL16 level before treatment in patients with NSCLC was 3.5 (2.0–8.1) ng/mL, which was significantly higher than that in age‐matched healthy adults (2.1 ng/mL, P < 0.05).